



Research Article

ISSN : 2277-3657  
CODEN(USA) : IJPRPM

## ***Effect of GABA<sub>B</sub> Receptor Agonist (Baclofen) and Antagonist (Saclofen) on Pain Relief in Rats***

**Seyyed Hamid Bathaei<sup>1\*</sup>, Hossein Kargar Jahromi<sup>2</sup>**

<sup>1</sup>Institution of Supreme Education and Industry of Maragheh, Iran.

<sup>2</sup>Research Center for Noncommunicable Diseases, Jahrom University of Medical Sciences, Jahrom, Iran

\*Corresponding Author: Seyyed Hamid Bathaei, Institution of Supreme Education and Industry of Maragheh, Iran.

\*Corresponding e-mail: [hamidbathae@gmail.com](mailto:hamidbathae@gmail.com) Tel: +989141781292

---

### ABSTRACT

*This study was conducted to investigate the effect of both baclofen and saclofen in acetic acid induced visceral pain in rats. In this study, adult male Wistar rats with a weight range of 250-200 g purchased from Tehran School of Veterinary Medicine were employed. All experiments were performed in 8 to 15 intervals and each animal was used once. In this study, sterile normal saline solution, a 1% acetic acid solution was used. Standard writhing Test was used to create and examine visceral pain. For visceral pain by writhing method, intraperitoneal injection of 1% acetic acid into the animal was employed. After intraperitoneal injection, visceral pain response was studied in doses of 2.5, 5 and 10 mg per kg of body weight. Each experiment was conducted based on completely randomized design with 6 replications. PROC GLM in SAS software (9.3) was used to compare the mean. In each test, Duncan and Dennett's tests were used to compare means in each test as well as for comparing means in control group. The results of pre-injection of saclofen in a 1 mg per kg of body weight before 5.2 mg baclofen injection per kilogram of body weight, has demonstrated that saclofen prevented from analgesic effect of baclofen,  $p$ -value  $<0/05$ . It can be said that the activation of GABAergic system in visceral pain by injecting both saclofen and baclofen decreased pain.*

**Keywords:** Baclofen, Saclofen, GABAergic system, rats, pain reduction

---

### INTRODUCTION

Pain is one of the most complex and extraordinary senses in humans. It is the most common symptom of diseases and common reason for visiting the doctor. Nociceptive pain includes not only stimulate the nerve fibers and transfer it to the center console of pain, but also can be changed by influencing by the quantity and quality of a wide range of experiences. This shows complex neural mechanisms for intervention and psychological response to pain experience (1, 2). Receptors are defined as free nerve endings that don't adapt unlike other sensory receptors in the body, or their adaptation is incredibly low. This non-adaptation allows the pain receptors to make aware person of damage stimulus that cause pain. The pain receptors are sensitive to chemical, mechanical, and thermal stimuli, and followed by tissue damage and release, chemical mediators such as bradykinin, histamine and prostaglandin are stimulated and send the pain signals by nerves to the central nervous system and eventually will feel pain by stimulating the cerebral cortex (3).

In addition, visceral pain is the complex pain that results from the stimulation of pain receptors in different organs of the body such as the colon, bladder and stomach in a variety of pathophysiological reasons and data is transmitted to

the central nervous system by afferent pathways. According to various studies, neurotransmitters participating in opioid and non-opioid analysis of pain are divided into two categories. The two systems can closely work together to regulate pain mechanisms. Non-opioid systems can be categorized as adrenergic, cholinergic, serotonergic, histaminergic and GABAergic systems (4). Gamma-Aminobutyric acid (GABA) has been proposed as Paracrine and autocrine factors compounds for regulating the activity of B cells (5, 6). GABA is mainly found in neurons and central nervous system (CNS) which has an inhibitory effect, although in some tissues, their irritation effects have also been reported. The presence of mediator has also been reported in other tissues including pancreas (7). Immunocytochemistry studies have shown that GABA and its sanitizer's enzyme, i.e. decarboxylase glutamate are also present in A and B cells (8). It was found that GABA in CNS has three receptors, which its two receptors are belonged to Aino receptors ( $GABA_A$ ) and ( $GABA_C$ ) and meta- receptors ( $GABA_B$ ). The expression of the beta cells has also been demonstrated (9). In relation to the effect of GABA mechanism on B cells, there is no complete agreement. Some studies have reported that GABA acts through  $GABA_B$  receptor. It has been shown that  $GABA_B$  receptor agonist baclofen have analgesic activity in humans and animals (10-12). Baclofen creates analgesia (11). It acts through spinal cord and supraspinal parts in the body (13) and is mainly recognized as antispasmodic agent for clinical use and reduces pain associated with spasticity (14) and also is useful in the treatment of trigeminal nerve (15). The involvement of neurotransmitters in the pharmacological effects of baclofen has been shown to support by the results of biochemical studies that baclofen had a significant impact on the content, release, construction and demolition these factors (13). In terms of pharmacological properties, subtypes of GABA receptors, were introduced as the first recipients of GABA antagonists. In Faklofen structure, baclofen carboxylic acid group is replaced by phosphonic acid. Compared with solphonic, saclofen resembles to 2-hydroxy acid. Saclofen with  $C_9H_{12}ClNO_3S$  chemical formula is a chemical compound with the 122 150 formula ID. Its molar mass is 249, 714 g mol (16). Therefore, the aim of this study was to investigate the effects of  $GABA_B$  receptor agonist (baclofen) and antagonist (saclofen) on visceral pain induced by acetic acid in rats.

### Materials and Methods

In this study, adult male Wistar rats with a weight range of 250-200 g purchased from Tehran School of Veterinary Medicine were used. Mice were kept in groups of six in polyethylene cages, and a room with environmental conditions and standard temperature of  $2 \pm 23$  ° C 12 hours in light and darkness and fed a commercial pellet diet and had free access to food and water. All experiments were performed in the interval of 8 to 15 and each animal was used once. All the principles of laboratory animal care were taken into consideration in terms of standard laboratory temperature and humidity. In this study, sterile normal saline solution, a solution of 1% acetic acid was used: the solution was prepared of pure acetic acid and after dilution. Saclofen purchased from Sigma Company were used. In this study, Writhing Test as one of the standard tests was utilized to create and examine visceral pain. For visceral pain by Writhing method, acetic acid (1ml, 1%) was injected into the intraperitoneal area of the animal. Before the test, to avoid stress as well as habituate the animals to laboratory conditions, animals were kept in a glass container with dimensions  $20 \times 30 \times 40$  cm for 30 minutes (which it is called the period of adaptation) so that the animal may be adapted to new conditions. After adaptation period, the animal was slowly brought out of the enclosure glass and after the drug's injection, the peritoneal injection of one ml acetic acid was carried out and immediately the animal was put in the chamber glass. Moreover, latency time (Latency Time) and time to first abdominal cramps and number of contractions for an hour with an interval of five minutes of acetic acid infusion were recorded in special forms. A device called pain mirror was used to check visceral pain. The device has a wooden frame, a glass cube container with  $20 \times 30 \times 40$  cm and a mirror the size of  $30 \times 40$  cm with an angle of 45 degrees inside it. While creating and recording of abdominal cramps in the animal, the mirror makes viewing more comfortable. After injection of saclofen for 5 mg per kg of body weight, visceral pain response was studied. Each experiment was conducted based on completely randomized design. PROC GLM in SAS software (9.3) was used to compare the mean. In each test, Duncan and Dennett's tests were used to compare means in each test as well as for comparing means in control group.

### Results

The results of pre-injection of saclofen in dose of 1 mg per kg of body weight before the injection of baclofen in 2.5 mg per kg of body weight has demonstrated that saclofen prevented from baclofen analgesic effect, p-value <0/05.

**Table 1.** The main effects of acetic acid Conclusion

Writhing test (NO)	Latency time (sec)		
2/035 <sup>b</sup>	<sup>a</sup> 01478/0	/5	Acid acetic
12/375 <sup>a</sup>	<sup>b</sup> 466/0		Acid acetic
9/208 <sup>a</sup>	<sup>b</sup> 386/8		Acid acetic
1/615	79.812%	SEM	
0.0013%	00010/<	P-value	

**Table 2.** Effects of different doses of baclofen and saclofen

Writhing test (NO)	Latency time (sec)	
7/791 <sup>a</sup> 1/624 <sup>b</sup> 1/180 <sup>b</sup>	918/833 <sup>ab</sup>	Saclofen 0 mg/kg + baclofen 0 mg/kg + 1% acetic acid
	806/583 <sup>ab</sup>	Saclofen 1 mg/kg + baclofen 0 mg/kg + 1% acetic acid
	962/883 <sup>a</sup>	Saclofen 0mg/kg + baclofen 5 / 2 mg/kg+ acetic acid 1%
	1046/416	Saclofen mg/kg1 + baclofen 5 / 2 mg/kg+ acetic acid 1%
0/085	72/419	SEM
0/0433	0/0142	P-value

### Discussion and conclusion

Since no many studies have been done on analgesic effect of saclofen in rats, and because GABA has been shown as an inhibitory neurotransmitter in the central nervous system in mammals, showing the relationship between saclofen and GABAergic system in the modulation of visceral pain is important. It seems that each opioid receptor has a separate specific activity. In mice where their opioid receptors were knocked out,  $\mu$  pain receptors were affected in response to chemical, mechanical and thermal pains in supraspinal part. K receptors in the spinal cord mediate visceral, thermal and chemical pain as well as  $\delta$  receptors mediate mechanical and inflammation pains (17). Studies in this research revealed the therapeutic ineffectiveness of the GABAB receptor antagonists especially saclofen (17). Research conducted on mice has shown that baclofen and saclofen suppressed some substances, such as nicotine and methamphetamine (19-21). Zai and Stein reported that baclofen reduced self-prescription of heroin in rats (21). And two other studies have shown that baclofen decreases symptoms of opioid withdrawal in morphine -dependent animals (11, 23). In this study, it has been shown that the effect of both agonists and antagonists is expected to reduce abdominal pain. It has been shown in some studies that various concentrations of GABA receptor antagonist (saclofen) in the presence of 16.7 mM glucose showed that saclofen increased stimulated insulin secretion from the islets of Langerhans. Findings from studies in cells A, B, and D from islets of Langerhans in cultured rat have shown that in the presence of GABAB receptor antagonists (CGP5584), stimulated insulin secretion by glucose from B cells is increased, but the secretion of glucagon and somatostatin secreted from A and D cells; respectively, had no effect (24). On the other hand, activation of GABAergic system in visceral pain by injecting both saclofen

and baclofen as GABAB receptor antagonists reduced pain in mentioned part. In the end, we can conclude that there is an association between visceral pain, opioids and GABAergic systems which has somewhat proven in the present study. In conclusion, there is a need for more studies on the use of saclofen and baclofen.

#### References:

1. Cervero F, Laird JM. Mechanisms of touch-evoked pain (allodynia): a new model. *Pain*. 1996;68(1):13-23.
2. Krnjevic K. GABA-mediated inhibitory mechanisms in relation to epileptic discharges. *Basic mechanisms of neuronal hyperexcitability*: Alan R. Liss New York; 1983. p. 249-80.
3. Ness TJ, San Pedro EC, Richards JS, Kezar L, Liu H-G, Mountz JM. A case of spinal cord injury-related pain with baseline rCBF brain SPECT imaging and beneficial response to gabapentin. *Pain*. 1998;78(2):139-43.
4. Mohammad Radmehr, Hossein Kargar Jahromi, Hassanali Abedi, Vahid Seifi, Saina Karami, Zahra Kargar Jahromi. Comparison of the Effect of Lycopene with Ibuprofen on Sensory Threshold of Pain Using Formalin Test in Adult Male Rats. *Journal of Chemical and Pharmaceutical Research*, 2016, 8(4):1322-1327.
5. Adeghate E, Ponery A. GABA in the endocrine pancreas: cellular localization and function in normal and diabetic rats. *Tissue and Cell*. 2002;34(1):1-6.
6. Storm-Mathisen J, Leknes AK, Bore AT, Vaaland JL, Edminson P, Haug F, et al. First visualization of glutamate and GABA in neurones by immunocytochemistry. *Nature*. 1983;301(5900):517-20.
7. Franklin IK, Wollheim CB. GABA in the endocrine pancreas its putative role as an islet cell paracrine-signalling molecule. *The Journal of general physiology*. 2004;123(3):185-90.
8. Gomez R, Asnis N, Tannhauser SL, Barros HM. GABA agonists differentially modify blood glucose levels of diabetic rats. *The Japanese Journal of Pharmacology*. 1999;80(4):327-31.
9. Vicini S. New perspectives in the functional role of GABAA channel heterogeneity. *Molecular neurobiology*. 1999;19(2):97-110.
10. Aley K, Kulkarni S. Baclofen analgesia in mice: a GABAB-mediated response. *Methods and findings in experimental and clinical pharmacology*. 1991;13(10):681-6.
11. Zarrindast M, Djavdan M. GABAA-antagonists and baclofen analgesia. *General Pharmacology: The Vascular System*. 1988;19(5):703-6.
12. Anghinah R, Oliveira A, Gabbai A. Effect of baclofen on pain in diabetic neuropathy. *Muscle & nerve*. 1994;17(8):958-9.
13. Sawynok J. GABAergic mechanisms of analgesia: an update. *Pharmacology Biochemistry and Behavior*. 1987;26(2):463-74.
14. Young R, Delwaide P. Drug therapy: spasticity (first of two parts). *The New England journal of medicine*. 1981;304(1):28.
15. Fromm GH, Terrence CF, Chattha AS. Baclofen in the treatment of trigeminal neuralgia: Double-blind study and long-term follow-up. *Annals of neurology*. 1984;15(3):240-4.
16. Kerr DJ, Ong J, Johnston GA, Abbenante J, Prager RH. Antagonism at GABA B receptors by saclofen and related sulphonic analogues of baclofen and GABA. *Neuroscience letters*. 1989;107(1):239-44.
17. Vaez G, Tavasoli Z, Ranjbar-Bahadori S. Study on the different dosages of *Elaeagnus angustifolia* aqueous extract with and without morphine on the antinociceptive rate in mice. *Research in Medicine*. 2011; 35 (1) :27-33.
18. Cousins MS, Roberts DC, de Wit H. GABA B receptor agonists for the treatment of drug addiction: a review of recent findings. *Drug and alcohol dependence*. 2002;65(3):209-20.
19. Shoab M, Swanner L, Beyer C, Goldberg S, Schindler C. The GABAB agonist baclofen modifies cocaine self-administration in rats. *Behavioural pharmacology*. 1998.

20. Campbell UC, Lac ST, Carroll ME. Effects of baclofen on maintenance and reinstatement of intravenous cocaine self-administration in rats. *Psychopharmacology*. 1999;143(2):209-14.
21. Roberts DC, Andrews MM, Vickers GJ. Baclofen attenuates the reinforcing effects of cocaine in rats. *Neuropsychopharmacology*. 1996;15(4):417-23.
22. Xi Z-X, Stein EA. Increased mesolimbic GABA concentration blocks heroin self-administration in the rat. *Journal of Pharmacology and Experimental Therapeutics*. 2000;294(2):613-9.
23. Bexis S, Ong J, White J. Attenuation of morphine withdrawal signs by the GABA B receptor agonist baclofen. *Life sciences*. 2001;70(4):395-401.
24. Braun M, Wendt A, Buschard K, Salehi A, Sewing S, Gromada J, et al. GABAB receptor activation inhibits exocytosis in rat pancreatic  $\beta$ -cells by G-protein-dependent activation of calcineurin. *The Journal of physiology*. 2004;559(2):397-409.